NCT04612725: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04612725 |
|---|---|
| Title | A Phase 2b Multinational, Randomised, Double-blind, Parallel- Group, 24-week Placebo-controlled Study With 28-week Extension to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 27, 2020 |
| Completion date | Oct. 13, 2022 |
| Required reporting date | Oct. 13, 2023, midnight |
| Actual reporting date | Oct. 10, 2023 |
| Date last checked at ClinicalTrials.gov | Sept. 4, 2025 |
| Days late | None |